Opinion

Video

Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease

Experts on Alzheimer disease discuss how the introduction of disease-modifying therapies has impacted the treatment landscape.

Video content above is prompted by the following question(s):

  • What has been the clinical impact and the target patients for the use of anti-amyloid β monoclonal antibodies?
    • Aducanumab approved by the FDA in 2021; development and commercialization discontinued on Jan 31, 2024
    • Lecanemab approved by the FDA in 2023

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Carrie Kitko
Dr Ibrahim Aldoss
1 expert is featured in this series.
Miriam Freimer, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo